[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"kidney-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:kidney-disease":32},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,39,0,25,[9,53,93,119,131,156,190,221,245,269,295,326,354,379,411,434,463,500,530,555,582,616,639,668,701],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":36,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":4},"100053567","early-phase-1-team-based-shared-decision-making-program-in-cardiovascular-kidney-metabolic-health-100053567",false,"NCT07662616","Team-Based Shared Decision-Making Program in Cardiovascular-Kidney-Metabolic Health","Feasibility and Efficacy Pilot of a Team-Based Shared Decision-Making Program in Cardiovascular-Kidney-Metabolic Health, Medication Adherence, and Cardiovascular Health","SDM in CKM","Inclusion Criteria:\n\n* Are adults aged 30 to 79 years (to use PREVENT equations to calculate 10- and 30-year risk estimates for total CVD),\n* Are in stage 2 CKM: the presence of metabolic risk factors (hypertension \\[stages 1 and 2\\], hypertriglyceridemia \\[≥135 mg\u002FdL\\], diabetes, Metabolic Equivalents (MetS)\\*) and\u002For Chronic Kidney Disease (CKD) \\[moderate- to high-risk CKD which are stages 1-3 CKD\\]), and\n* Receive primary care at Johns Hopkins Community Physicians (JHCP).\n* Access to smart phone or tablet to use app.\n\nExclusion Criteria:\n\n* Have diagnosis of CVD,\n* Stage 4-5 CKD, kidney failure, or on dialysis\n* Have a serious medical condition such as cancer;\n* On or planning to start Glucagon-like peptide-1 (GLP-1) receptor agonists in next 6 months;\n* Have cognitive impairment;\n* Are currently involved in other programs on improving LE8; or\n* Unwillingness to provide informed consent\n* Unable to speak, read, or communicate in English.","ALL","30 Years","79 Years",{"count":22,"type":23},94,"ESTIMATED","INTERVENTIONAL",[26],"EARLY_PHASE1","The investigators are proposing a new team-based shared decision-making (SDM) program. The goal of this study is to see whether this program is practical and whether it may help adults with cardiometabolic risk factors and cardiovascular-kidney-metabolic syndrome. The investigators will enroll adults from a primary care clinic in Maryland. People in the intervention group will take part in the 6-month program in addition to usual care. People in the control group will receive usual care only.",[29,30,31,32,33,34,35],"Hypertension (HTN)","Diabetes (DM)","Hyperlipidaemia","Kidney Disease","Obesity","Cardiovascular-kidney-metabolic (CKM)","Overweight",[37,38,39,40],"shared decision-making","Cardiovascular-kidney-metabolic","Behavioral counseling","Team-based care","NOT_YET_RECRUITING","2026-07-10",{"date":44,"type":45},"2026-07-13","ACTUAL",{"date":47,"type":23},"2026-08-10",{"date":49,"type":23},"2028-06-30",{"name":51,"class":52},"Johns Hopkins University","OTHER",{"id":54,"slug":55,"hasResults":12,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":12,"sex":18,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":24,"phases":64,"briefSummary":66,"conditions":67,"keywords":72,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":92},"100645075","comparison-of-the-effects-of-general-anesthesia-and-combined-spinal-epidural-anesthesia-on-ferroptosis-humanin-and-mots-c-levels-in-renal-transplantation-100645075","NCT07678073","COMPARISON OF THE EFFECTS OF GENERAL ANESTHESIA AND COMBINED SPINAL-EPIDURAL ANESTHESIA ON FERROPTOSIS, HUMANIN, AND MOTS-C LEVELS IN RENAL TRANSPLANTATION","COMPARISON OF THE EFFECTS OF GENERAL ANESTHESIA AND COMBINED SPINAL-EPIDURAL ANESTHESIA ON FERROPTOSIS, HUMANIN, AND MOTS-C LEVELS IN RENAL TRANSPLANTATION: A PROSPECTIVE CONTROLLED STUDY","Inclusion Criteria:\n\n* Patients aged 18-70 years with American Society of Anesthesiologists (ASA) physical status I-III.\n* Patients scheduled for elective living-donor allogeneic kidney transplantation.\n* Patients receiving sevoflurane-based general anesthesia as the anesthetic technique.\n* Patients receiving combined spinal-epidural anesthesia as the anesthetic technique.\n\nExclusion Criteria:\n\n* Patients younger than 18 years or older than 70 years.\n* Patients undergoing deceased-donor kidney transplantation.\n* Patients receiving total intravenous anesthesia (TIVA).\n* Patients who decline to participate in the study or are unable to provide informed consent.\n* Patients with American Society of Anesthesiologists (ASA) physical status IV or V.\n* Patients with a history of previous organ transplantation.\n* Patients with known or suspected mitochondrial disorders.\n* Patients with a history of chronic corticosteroid use.\n* Patients requiring red blood cell transfusion intraoperatively or within the first 24 postoperative hours.\n* Patients with a primary warm ischemia time \\>5 minutes, secondary warm ischemia time \\>30 minutes, or cold ischemia time \\>60 minutes.","18 Years","70 Years",{"count":63,"type":23},68,[65],"NA","Renal transplantation is the most effective renal replacement therapy for patients with end-stage renal disease. Ischemia-reperfusion injury may adversely affect graft function and long-term outcomes. Ferroptosis has recently emerged as a potential mechanism involved in ischemia-reperfusion injury, while the mitochondrial-derived peptides humanin and MOTS-c are thought to exert protective effects against oxidative stress. However, the effects of different anesthetic techniques on these biomarkers in kidney transplant recipients have not been investigated.\n\nThis prospective controlled study aims to compare the effects of sevoflurane general anesthesia (SGA) and combined spinal-epidural anesthesia (CSEA) on serum ferroptosis markers, humanin, and MOTS-c levels in adult kidney transplant recipients. Blood samples will be obtained perioperatively for biomarker analysis.\n\nThe primary objective of the study is to evaluate the effects of the anesthetic technique on serum ferroptosis markers, humanin, and MOTS-c levels. Secondary objectives include evaluating early graft function and postoperative outcomes by assessing the incidence of delayed graft function, postoperative serum creatinine levels, requirement for dialysis, urine output, length of hospital stay, and the association of these outcomes with perioperative biomarker levels.",[68,69,70,32,71],"Kidney Disease, End-Stage","Kidney Transplant","Kidney","Renal Transplant",[73,74,75,76,77,78,79,80,81],"GENERAL ANESTHESIA","REGIONAL ANESTHESIA","KIDNEY TRANSPLANTATION","CELLULAR STRESS RESPONSE","CELLULAR STRESS","ANESTHESIA","HUMANIN","MOTS-c","FERROPTOSIS","RECRUITING","2026-06-24",{"date":85,"type":45},"2026-07-01",{"date":87,"type":45},"2026-03-01",{"date":89,"type":23},"2026-10-15",{"name":91,"class":52},"University of Gaziantep",1,{"id":94,"slug":95,"hasResults":12,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":12,"sex":18,"minAge":60,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":24,"phases":102,"briefSummary":104,"conditions":105,"keywords":106,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":118},"100590162","phase-3-a-study-of-mezagitamab-in-adults-with-kidney-condition-called-iga-nephropathy-100590162","NCT06963827","A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy","A Phase 3 Multicenter, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate Efficacy and Safety of Mezagitamab (TAK-079) in Study Participants With Primary IgA Nephropathy in Combination With Stable Background Therapy","* Inclusion Criteria:\n\nTo be eligible to participate in this trial, participants must meet all the following criteria:\n\n1. Either UPCR greater than or equal to (≥) 0.8 gram per gram (g\u002Fg) or urine protein excretion (UPE) ≥1 grams per day (g\u002Fday), calculated from at least one 24-hour urine collection during the screening period (or pre-screening, if applicable) (only applicable for the main trial).\n2. eGFR greater than (\\>)30 milliliters per minute per 1.73 meter square (mL\u002Fmin\u002F1.73m\\^2) at screening based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula (only applicable for the main trial).\n3. No prior exposure to anti- cluster of differentiation 38 (CD38) therapy period (except for open-label cohort participants meeting Inclusion Criterion No. 10.a).\n4. The participant is aged ≥ 18 years or the local legal age as applicable.\n5. The participant (and the participant's legally acceptable representative, as applicable per local regulations or determination) has provided informed consent (that is, in writing, documented via a signed and dated informed consent form \\[ICF\\]) and any required privacy authorization before the initiation of any clinical trial procedures.\n6. Diagnosis of primary immunoglobulin A nephropathy (IgAN) supported by a renal biopsy report that is dated more recently than 10 years before the signing of the informed consent for the clinical trial. The redacted report must be made available for review. A renal biopsy must be performed during screening for participants without a biopsy report within 10 years.\n7. Participants must be on stable renin-angiotensin-aldosterone system (RAAS) inhibitor therapy with an angiotensin-converting enzyme inhibitor (ACE-I) and\u002For angiotensin receptor blocker (ARB) or endothelin receptor antagonist (ERA) or mineralocorticoid receptor antagonist (MRA) agent for at least 12 weeks before signing the ICF with dosing at the maximally tolerated or labeled dose as determined by the investigator, with the intent to continue stable dosing during the clinical trial. Those intolerant of RAAS inhibitor therapy are potentially eligible after consultation with the medical monitor. Intolerance is defined as a documented side effect causing discontinuation of the therapy.\n8. Resting blood pressure less than or equal to (≤)150 millimeters of mercury (mmHg) systolic and ≤100 mmHg diastolic.\n9. Female participants of childbearing potential who are not pregnant during screening (confirmed by negative serum human chorionic gonadotropin \\[hCG\\]) and on Visit 1 before first dose of trial intervention (confirmed by negative urine pregnancy test).\n10. Any one of the following (only applicable for participants in the open-label cohort):\n\n    1. Participants in Trial TAK-079-1006 who completed the Week 96 visit or the retreatment period with either UPCR \\>0.5 g\u002Fg or UPE \\>0.5 g\u002Fd calculated from a 24-hour urine collection during the screening period (or pre-screening, if applicable) and eGFR \\>30 mL\u002Fmin\u002F1.73m\\^2 at screening based on the CKD-EPI formula.\n    2. UPCR \\\u003C0.8 g\u002Fg and UPE ≥0.75 and \\\u003C1.0 g\u002Fday, by 24-hour urine collection during the screening period (or pre-screening, if applicable) and eGFR \\> 30 mL\u002Fmin\u002F1.73m\\^2 at screening based on the CKD-EPI formula.\n    3. UPCR ≥ 0.8 g\u002Fg or UPE ≥ 1.0 g\u002Fd by 24-hour urine collection during the screening period (or pre-screening, if applicable) and eGFR ≥25 and ≤30 mL\u002Fmin\u002F1.73m\\^2 at screening based on the CKD-EPI formula.\n\n       * Exclusion Criteria:\n\nA participant who meets any of the following criteria will be excluded from participation in this trial:\n\n1. Kidney biopsy exhibiting significant concomitant renal disease other than IgAN (for example, diabetic nephropathy, lupus nephritis, minimal change disease).\n2. Secondary IgAN (such as with significant liver disease, inflammatory bowel disease, and seronegative spondyloarthropathies), and immunoglobulin A (IgA) vasculitis.\n3. Evidence of rapidly progressive glomerulonephritis (loss of ≥50% of eGFR within 3 months before the signing of the ICF).\n4. Diagnosis of nephrotic syndrome defined as 24-hour proteinuria \\>3.5 g\u002Fday and hypoalbuminemia (\\\u003C3.0 grams per deciliter \\[g\u002FdL\\]) with or without peripheral edema.\n5. Renal or other organ transplantation prior to or expected during the clinical trial.\n6. Treatment with oral immunosuppressive agents (including cyclophosphamide, mycophenolate mofetil, cyclosporine, azathioprine, calcineurin inhibitors) or biologic therapy for immunomodulation (including immunomodulatory monoclonal or polyclonal antibodies) within 6 months (both B-cell and non-B-cell directed agents) before signing of the ICF.\n7. If the participant has received anti-CD20 treatment, the participant is excluded if either of the following apply:\n\n   1. The last dose was received within 6 months before the signing of the ICF.\n   2. The last dose was received between 6 and 12 months before the signing of the ICF and the participant has a CD19+ count below the lower limit of normal.\n\n   Note: Participants who have received the last dose of anti-CD20 treatment \\>12 months before the signing of the ICF are not excluded from clinical trial participation based on this criterion and are not required to undergo CD19+ testing.\n8. Within 4 months of the screening visit, use of either a) systemic corticosteroids at an average dose of 40 milligrams (mg) prednisone equivalent or higher for more than 14 days or b) oral budesonide delayed release capsules.\n9. The participant has received a live or live-attenuated vaccine within 4 weeks before signing the ICF or has any live or live-attenuated vaccine planned during the clinical trial.\n10. Participation in any other investigational drug trial (including vaccine trial) with receipt of at least 1 dose of investigational drug, or has been exposed to another investigational agent within 4 weeks or 5 half-lives, whichever is longer, before Visit 1.\n11. The participant has active infection with hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV).\n12. The participant has had any of the following types of infections within the specified timeframes where applicable:\n\n    1. Active bacterial, viral, or fungal infection (except for the common cold and onychomycosis), or any other serious infection within 2 weeks of signing the ICF. Any anti-infective course for infection must be completed at least 2 weeks before Visit 1.\n    2. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) infection within 4 weeks of signing the ICF.\n    3. Opportunistic infection or treatment for an opportunistic infection less than or equal to (≤)12 weeks before signing the ICF.\n    4. Active tuberculosis (TB), any history of prior active TB, or any signs or symptoms of active TB infection (including but not limited to chronic fever, chronic productive cough, night sweats, weight loss, or malnutrition) as judged by the investigator.\n    5. For participants in European Union (EU) member states, positive or 2 indeterminant QuantiFERON results, unless there is documentation of prior complete treatment for latent TB, or participant has initiated prophylaxis based on local guidelines and in consultation with a pulmonology or infectious disease specialist prior to the first administration of IMP.\n13. In the opinion of the investigator, the participant is currently experiencing any medical condition that might interfere with participation in the trial (for example, significant ocular, cardiovascular, pulmonary, hematologic, gastrointestinal, endocrinologic, hepatic, renal, neurologic, malignancy, infectious disease, immunodeficiency, or alcohol and drug abuse), that poses an added risk for the participant or could confound the assessment of trial results.\n14. In the opinion of the investigator, the participant has a serious medical or psychiatric illness that could potentially interfere with the completion of treatment.\n15. The participant has a history of major surgery within 3 months before screening (or longer, at the discretion of the investigator); or, either has a planned tonsillectomy or underwent a tonsillectomy within 6 months before screening.\n\n    Note: Major surgery typically requires at least 1 night in the hospital.\n16. History of malignancy (including myelodysplastic syndrome) within 5 years of signing the ICF, except for adequately treated non-melanoma skin cancer, superficial bladder cancer, and curatively treated cervical carcinoma-in-situ.\n17. The participant has a history of a severe allergic or anaphylactic reaction to recombinant proteins or excipients used in the mezagitamab or placebo formulation.\n18. The participant has (1) been diagnosed with or has suspected chronic obstructive pulmonary disease (COPD) or asthma and (2) has a prebronchodilatory forced expiratory volume in 1 second (FEV1) \\\u003C50% of predicted normal at screening.\n19. The participant is capable of breastfeeding but does not agree to forego breastfeeding from first dose of investigational medicinal product (IMP) through 30 days after the last dose of IMP.\n20. The participant is an individual with potential for pregnancy but does not agree to use at least 1 form of highly effective contraception and 1 barrier method of contraception (preferably male condom) when engaging in heterosexual sex for the protocol specified duration after the last dose of IMP.\n21. The participant is a sexually active, non-sterilized individual who produces sperm but does not agree to use a barrier method (preferably male condom) combined with at least 1 form of highly effective contraception for any partner(s) with potential for pregnancy when engaging in heterosexual sex for the protocol specified duration after the last dose of IMP.\n22. In the investigator's opinion, the participant (and the participant's legally acceptable representative, if applicable per local regulations or determination) is unwilling and\u002For unable to understand and fully comply with clinical trial procedures and requirements (including digital tools and applications).",{"count":101,"type":23},347,[103],"PHASE3","Immunoglobulin A nephropathy (IgAN) is a kidney condition. It happens when the body's immune system creates groups of proteins (called immune complexes) that build-up in the kidneys causing swelling (inflammation). Over time, this inflammation may lead to kidney damage and cause the kidneys to no longer work properly. The main aim of this study is to check how well mezagitamab changes protein levels in the urine (proteinuria) compared to placebo in adults with primary IgAN. A placebo looks like medicine but doesn't have any active ingredients in it. Other aims are to check how safe mezagitamab is and how well participants with primary IgAN can tolerate it compared to placebo, and to find out if and how well mezagitamab continues to maintain kidney function over the long term compared to placebo.\n\nParticipants will be placed in 1 of the 2 treatment groups; the main group and the open-label group. In the main group, participants will be placed in 1 of the 2 treatment groups by chance (either mezagitamab or placebo) at a 2:1 ratio. This means that out of 3 participants, 2 will receive mezagitamab and 1 will receive placebo. The participants will receive either mezagitamab or placebo for almost half a year in two 1-year cycles. They will be observed for another half year in each 1-year cycle and will have check-ups about every month during this time.\n\nIn the open-label group, a small number of participants who have lower levels of protein in their urine or have kidneys that do not filter the blood well, will receive mezagitamab treatment. This will include participants who have previously received mezagitamab in another study, TAK-079-1006. Every participant will receive mezagitamab in the same way as those in the main group receiving mezagitamab.\n\nDuring the study, participants will visit their study clinic several times.",[32],[107,108],"TAK-079","Drug Therapy","2026-06-23",{"date":83,"type":45},{"date":112,"type":45},"2025-07-15",{"date":114,"type":23},"2030-01-14",{"name":116,"class":117},"Takeda","INDUSTRY",170,{"id":120,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":121,"targetDuration":4,"studyType":24,"phases":122,"briefSummary":27,"conditions":123,"keywords":124,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":129,"leadSponsor":130,"locationsCount":4},"100643950",{"count":22,"type":23},[26],[29,30,31,32,33,34,35],[37,38,39,40],"2026-06-22",{"date":127,"type":45},"2026-06-25",{"date":85,"type":23},{"date":49,"type":23},{"name":51,"class":52},{"id":132,"slug":133,"hasResults":12,"nctId":134,"briefTitle":135,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":12,"sex":18,"minAge":60,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":24,"phases":139,"briefSummary":140,"conditions":141,"keywords":145,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":92},"100644010","efficacy-of-the-use-of-real-time-continuous-glucose-monitoring-on-glycemic-control-in-patients-with-type-2-diabetes-and-stage-3-and-4-chronic-kidney-disease-100644010","NCT07668219","Efficacy of the Use of Real-time Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes and Stage 3 and 4 Chronic Kidney Disease.","4.2.1 Inclusion Criteria\n\n* Age over 18 years\n* Chronic kidney disease defined as a glomerular filtration rate (GFR) of less than 60 ml\u002Fmin\u002F1.73 m², in at least two measurements within the six months prior to inclusion.\n* Treatment with basal insulin, basal-bolus regimen, or co-formulation with or without oral antidiabetic agents, with or without a GLP-1 analogue, with stable treatment for the last 3 months.\n\n4.2.2 Exclusion Criteria\n\n* Type 1 diabetes.\n* Severe cognitive impairment or dysfunction that prevents device management.\n* Chronic kidney disease on renal replacement therapy (peritoneal dialysis or hemodialysis).\n* Patients with a history of kidney transplantation.",{"count":138,"type":23},30,[65],"* Rationale: Glucose control in patients with kidney disease is challenging, as traditional metrics can be unreliable and there is a high risk of hypoglycemia (low blood sugar). Although RT-CGM has shown benefits in other groups, its efficacy in patients with advanced kidney damage needs to be validated to improve their quality of life and prevent disease progression.\n* Main objective: To determine whether the use of RT-CGM is more effective than usual care (capillary blood glucose monitoring with a glucometer) in maintaining patients within an optimal glucose range (70-180 mg\u002FdL) over a three-month period.\n* Study population: We plan to include 30 patients over 18 years of age with type 2 diabetes and chronic kidney disease (with a glomerular filtration rate less than 60 ml\u002Fmin), who use insulin and are not on renal replacement therapy such as dialysis.\n* Methodology: The study is a randomized clinical trial consisting of two phases:\n\n  1. Selection period (15 days): Blinded monitoring is performed to obtain baseline data.\n  2. Treatment period (90 days): Patients are divided into two groups: the intervention group, which will use the CGM-RT with alarms configured for high and low levels, and the control group, which will continue with traditional fingerstick monitoring.\n* Metrics to be evaluated: In addition to time in range, researchers will analyze episodes of hypoglycemia and hyperglycemia, glycemic variability, glycated hemoglobin (HbA1c) levels, and device accuracy.\n* Ethical and logistical considerations: The study complies with international and national regulations, guaranteeing the confidentiality and autonomy of the participants. The project has a 24-month timeline and a detailed budget to cover medical personnel, monitoring sensors (Sinocare i3), and laboratory tests.",[142,32,143,144],"Type 2 Diabetes","CGM","Time in Range",[142,32,146,147],"Continuous Glucose Monitoring","Time in range","2026-06-19",{"date":127,"type":45},{"date":151,"type":23},"2026-11",{"date":153,"type":23},"2027-05-30",{"name":155,"class":52},"Hospital Universitario San Ignacio",{"id":157,"slug":158,"hasResults":12,"nctId":159,"briefTitle":160,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":12,"sex":18,"minAge":60,"maxAge":162,"enrollmentInfo":163,"targetDuration":4,"studyType":24,"phases":165,"briefSummary":167,"conditions":168,"keywords":173,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":92},"100636992","phase-1-adia-med-of-winter-park-llc-chronic-kidney-disease-research-study-100636992","NCT07572890","Adia Med of Winter Park LLC Chronic Kidney Disease Research Study","Inclusion Criteria:\n\n* Age 18-80 years\n* Confirmed CKD diagnosis (eGFR 15-89 mL\u002Fmin\u002F1.73 m²)\n* Willingness to consider experimental treatments and comply with study requirements\n* Ability to obtain required bloodwork\n* Ability to attend all scheduled visits\n* Able to meet study cost requirements ($15,000 study fee) as described in the informed consent\n\nExclusion Criteria:\n\n* Has\n* Severe allergies to study products\n* Significant uncontrolled medical conditions\n* Immunocompromised\n* Malignancy history\n* Unstable medication regimen or inconsistent medication adherence (e.g., frequent medication changes or missed doses) within 30 days prior to Baseline, at Investigator discretion\n* Current dialysis (hemodialysis or peritoneal dialysis) or planned initiation of dialysis during the study period\n* Pregnancy or breastfeeding (if applicable)\n* Participation in another interventional trial within 30 days\n* Has had Kidney transplant\n* Prior stem cell or glutathione therapy: History of stem cell therapy (including umbilical cord blood-derived stem cells or exosomes) or glutathione therapy (intravenous or topical) at any time prior to screening","80 Years",{"count":164,"type":23},100,[166],"PHASE1","The goal of this clinical trial is to learn whether a new regenerative treatment called AdiaVita, made from umbilical cord blood-derived stem cells and exosomes combined with glutathione, is safe and can help improve kidney function in adults with chronic kidney disease (CKD). In this condition, the kidneys gradually lose their ability to filter blood as well as they should. The main questions it aims to answer are whether AdiaVita plus glutathione improves kidney function better than control treatments, as measured by blood tests for estimated glomerular filtration rate (eGFR) and creatinine levels, and whether the treatment is safe with acceptable side effects. Researchers will compare three groups. One group will receive AdiaVita plus glutathione. A second group will receive glutathione plus a placebo for AdiaVita. The third group will receive placebos for both treatments. A placebo looks like the real treatment but contains no active ingredients. This will help determine if the full treatment works better than the controls. Approximately 100 adults aged 18 to 80 with stage 2 to 4 chronic kidney disease may participate. Participants will be randomly assigned to one of the three treatment groups. They will receive monthly intravenous infusions at the clinic for the first three months and apply a skin spray twice daily at home during that period. The study lasts 12 months total for each participant, with regular visits for blood tests, physical exams, and safety monitoring. Certain participants in the control groups may switch to the active AdiaVita treatment after three months if they meet safety criteria. This is a single-blind study, meaning participants will not know which treatment they receive. Participant safety is closely monitored by the research team and an independent board throughout the study.",[169,32,170,171,172],"Chronic Kidney Disease","Kidney Disease, Chronic","Chronic Kidney Disease (CKD)","CKD",[174,175,176,177,169,172,178,179,180],"allogeneic stem cells","antioxidant therapy","stem cell therapy","stem cells","Regenerative medicine","Glutathione","Glutathione therapy","2026-06-16",{"date":183,"type":45},"2026-06-17",{"date":185,"type":23},"2026-05-18",{"date":187,"type":23},"2029-01",{"name":189,"class":52},"Adia Med of Winter Park LLC",{"id":191,"slug":192,"hasResults":12,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":12,"sex":18,"minAge":60,"maxAge":4,"enrollmentInfo":198,"targetDuration":4,"studyType":24,"phases":200,"briefSummary":201,"conditions":202,"keywords":207,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":4},"100643135","the-adaptive-platform-trial-for-kidney-disease-100643135","NCT07595952","The Adaptive Platform Trial for Kidney Disease","APT-KIDNEY: The Adaptive Platform Trial for Kidney Disease","APT-KIDNEY","Eligibility Criteria - Inclusion\n\n1. Adults with age ≥18 years\n2. eGFR \\\u003C30 ml\u002Fmin\u002F1.73m² for ≥3 months or end-stage kidney disease on dialysis or Kidney transplant with functioning graft (any eGFR)\n3. Ability to provide informed consent\n4. Meets eligibility criteria for at least one currently active APT-KIDNEY domain\n\nEligibility Criteria - Exclusion\n\n1. Refusal to provide informed consent\n2. Participation in another interventional trial whose protocol prohibits co-enrollment in APT-KIDNEY\n3. Any condition that, in the investigator's judgment, makes participation in any APT-KIDNEY domain unsafe or impractical",{"count":199,"type":23},5000,[65],"Background: Randomized clinical trials (RCTs) are essential for evaluating intervention effects but are often challenged by regulatory and logistical burdens, high costs, and extended timelines. To address these challenges, the 'Adaptive Platform Trial in Kidney Disease' (APT-KIDNEY) will establish an investigator-initiated platform trial built on a unified regulatory, contractual, and operational framework. The platform emphasizes adaptive, cost-efficient methodology, automated data capture via linkage to electronic health records and administrative registers, and stakeholder engagement.\n\nObjectives: The primary objective of APT-KIDNEY is to establish an adaptive platform trial for evaluation of multiple interventions in patients with advanced kidney disease as defined by an estimated glomerular filtration rate \\\u003C 30 ml\u002Fmin\u002F1.73 m2 or end-stage kidney disease (ESKD) on dialysis or conservative care.\n\nStudy design: APT-KIDNEY is a pragmatic, randomized, embedded, multifactorial, adaptive platform trial with interventions organized into domains, emphasizing low-intervention comparisons. Domains may be open-label or blinded and will be able to use response-adaptive randomization, adaptive stopping and arm-dropping, and adaptive enrichment to enhance efficiency and relevance where applicable.\n\nStudy population: Adults (≥18 years) with advanced kidney disease defined by eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m2 for ≥3 months or ESKD on hemo- or peritoneal dialysis who are eligible for ≥1 one domain. Key exclusions include inability to provide informed consent; domain-specific exclusions may apply, but eligibility cannot be broadened beyond the core protocol.\n\nTrial outcomes: Core outcomes will be all-cause mortality, major adverse cardiovascular events (nonfatal myocardial infarction, nonfatal ischemic stroke, or cardiovascular death), and health-related quality of life (EQ-5D-5L).\n\nAbbreviated methods: APT-KIDNEY will permit domains to use frequentist and\u002For Bayesian methods. Primary analyses will target prespecified primary estimands and be conducted using the full analysis set. Prespecified sensitivity analyses will assess robustness to alternative strategies for intercurrent events and missing data, including per-protocol and as-treated supportive analyses. Outcomes are analyzed with generalized linear\u002Fmixed models and time-to-event methods with covariate adjustment. Frequentist analyses will be fixed-sample or group-sequential; results will be reported with 95% CIs and p-values, and Bayesian analyses will report posterior effects with 95% credible intervals and posterior probabilities. Bayesian domains will primarily use neutral, mildly skeptical priors. Multiplicity will be controlled at the domain level by a prespecified hierarchy: primary comparisons will precede secondary outcomes. Advanced adaptive domains will be evaluated by simulation to quantify operating characteristics including, power and Type I error, and the impact of outcome delays and missing data.\n\nPerspectives: APT-KIDNEY will establish an enduring, investigator-led platform for pragmatic, embedded nephrology trials, reducing start-up time and administrative burden through a shared regulatory and operational framework. Using standardized core outcomes and automated follow-up via electronic health records and national registers, it will generate faster, comparable, practice-relevant evidence across multiple interventions.",[32,203,204,205,206],"Chronic Kidney Disease (Stages 4 and 5)","End-Stage Kidney Disease (ESKD)","Dialysis","Kidney Transplantation",[208,209,210,211],"Chronic kidney disease","Kidney transplantation","End-stage kidney disease","Platform trial","2026-06-08",{"date":214,"type":45},"2026-06-10",{"date":216,"type":23},"2026-10-01",{"date":218,"type":23},"2066-12-31",{"name":220,"class":52},"Nicholas Carlson",{"id":222,"slug":223,"hasResults":12,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":12,"sex":18,"minAge":228,"maxAge":229,"enrollmentInfo":230,"targetDuration":4,"studyType":232,"phases":4,"briefSummary":233,"conditions":234,"keywords":236,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":240,"completionDateStruct":4,"leadSponsor":242,"locationsCount":92},"100054889","immune-system-related-kidney-disease-100054889","NCT00001979","Immune System Related Kidney Disease","Studies of Immunologically-Mediated Kidney Diseases","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, a participant must meet all of the following criteria:\n\n1. Adults \\>= 18 years of age and children 10-17 years of age\n2. Participants with\n\n   1. known, proven, or suspected immunologically-mediated kidney diseases, including but not limited to nephrotic syndrome, glomerulonephritis, membranous nephropathy, lupus nephritis, and nephritis associated with other systemic or connective tissue disorders, OR\n   2. immunologically-mediated diseases with the potential for kidney disease.\n3. Ability of the participant or guardian to understand and the willingness of the participant or guardian to provide written informed consent.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Concomitant medical problems which would confound the interpretation of studies of the immunologic kidney disorder.\n2. Concomitant medical, surgical, or other conditions for which inadequate facilities or funds are available to support their care at the NIH.","10 Years","99 Years",{"count":231,"type":23},2000,"OBSERVATIONAL","Kidney diseases related to the immune system include, nephrotic syndrome, glomerulonephritis, membranous nephropathy, lupus nephritis, and nephritis associated with connective tissue disorders.\n\nThis study will allow researchers to admit and follow patients suffering from autoimmune diseases of the kidney. It will attempt to provide information about the causes and specific abnormalities associated with autoimmune kidney disease.\n\nPatients with kidney disease as a result of their immune system, and patients with diseases of the immune system who may later develop kidney disease, will be potential subjects for this study.\n\nPatients will undergo a history and physical examination, and standard laboratory test to more closely understand the causes, signs, symptoms, and responses to medication of these diseases. Based on these evaluations the patients may qualify as candidates for other experimental studies. At any time these patients may be asked to submit blood or urine samples for further research.",[32,235],"Nephrotic Syndrome",[32,169,237],"Natural History","2026-06-05",{"date":212,"type":45},{"date":241,"type":45},"1992-06-25",{"name":243,"class":244},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","NIH",{"id":246,"slug":247,"hasResults":12,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":4,"eligibilityCriteria":251,"healthyVolunteers":252,"sex":18,"minAge":60,"maxAge":162,"enrollmentInfo":253,"targetDuration":4,"studyType":24,"phases":255,"briefSummary":256,"conditions":257,"keywords":4,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":268},"100595489","radiant-health-systems-intervention-100595489","NCT07033117","RaDIANT Health Systems Intervention","The RaDIANT Health Systems Intervention for Improving Access to Kidney Transplantation","Inclusion Criteria:\n\n* Five large transplant centers (Emory Transplant Center and Piedmont Transplant Center in Atlanta, GA; Medical University of SC; Duke University in Durham, NC; and Indiana University in Indianapolis, IN) \\~800 referring dialysis center referring to these transplant centers\n\nExclusion Criteria:\n\n* Individuals referred, initiating evaluation, and waitlisted at non-participating start centers",true,{"count":254,"type":23},14000,[65],"The overarching goal of the proposed study is to determine whether the addition of structural interventions at the health system level targeting upstream barriers in the transplant process will improve access to transplant evaluation start.",[258,32],"End Stage Renal Disease (ESRD)","2026-05-22",{"date":261,"type":45},"2026-05-26",{"date":263,"type":45},"2025-10-27",{"date":265,"type":23},"2027-07-31",{"name":267,"class":52},"Indiana University",5,{"id":270,"slug":271,"hasResults":12,"nctId":272,"briefTitle":273,"officialTitle":274,"acronym":4,"eligibilityCriteria":275,"healthyVolunteers":12,"sex":18,"minAge":60,"maxAge":4,"enrollmentInfo":276,"targetDuration":4,"studyType":232,"phases":4,"briefSummary":278,"conditions":279,"keywords":284,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":92},"100640196","clinical-information-system-impact-on-hospitalized-patients-with-chronic-disease-100640196","NCT07609381","Clinical Information System Impact on Hospitalized Patients With Chronic Disease","Evaluating the Impact of Alberta Health Services' New Provincial Clinical Information System on Patient Outcomes and Experiences With Chronic Diseases - Study Protocol for a Multi-center Interrupted Time Series Analysis","Inclusion Criteria:\n\n* Adults aged 18 years or older at the time of hospital admission.\n* Residents of Alberta eligible to receive acute-care services in AHS facilities.\n* Hospitalized for any cause during the study period (5 years pre-implementation and 2 years post-implementation of the CIS).\n* Meet the validated case definition for one or more of the five key NCDs (diabetes mellitus, chronic kidney disease, coronary artery disease, heart failure, or chronic lung disease) based on ICD codes, laboratory measures, or pharmacy records during standardized lookback periods (up to 5 years for diagnoses; up to 1 year for labs\u002Fpharmacy).\n* Have a qualifying date for the NCD(s) that occurs prior to or during the index hospital admission.\n* Eligible for inclusion in the primary and patient experience outcomes if they survive to hospital discharge.\n* May enter multiple sub-cohorts if more than one NCD is present.\n\nExclusion Criteria:\n\n* Individuals younger than 18 years at the time of hospital admission.\n* Non-residents of Alberta or individuals not eligible for care within AHS facilities.\n* Hospitalizations that end in death (excluded from analyses of the primary outcome and patient experience measures).\n* Patients without evidence of any of the five key NCDs during the lookback period or at the index hospital admission.\n* Admissions outside the study period or admissions for which necessary administrative, laboratory, or pharmacy data are unavailable.",{"count":277,"type":23},124240,"This is a retrospective, observational study using routinely collected information collected by Alberta Health Services. The study will identify patients with chronic disease, defined by one or more of the following conditions; diabetes mellitus, heart failure, coronary artery disease, chronic kidney disease, or chronic lung disease. Adult residents of Alberta with a chronic disease of interest present upon hospital admission and who survive to hospital discharge will be included in the study cohort. The primary outcome will be the composite of hospital readmission or death within 30 days of discharge. Secondary outcomes will include components of the composite, length of stay, patient experiences related to their hospital to home transition of care, and processes of care. Multi-level interrupted time series analysis will be used to compare outcomes before versus after implementation of the Connect Care CIS.",[280,32,281,282,283],"Diabete Mellitus","Heart Failure","Coronary Artery Disease","Chronic Lung Diseases",[285],"Clinical Information System","2026-05-19",{"date":288,"type":45},"2026-05-27",{"date":290,"type":23},"2026-06-01",{"date":292,"type":23},"2027-12-31",{"name":294,"class":52},"University of Calgary",{"id":296,"slug":297,"hasResults":12,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":4,"eligibilityCriteria":301,"healthyVolunteers":252,"sex":18,"minAge":302,"maxAge":303,"enrollmentInfo":304,"targetDuration":4,"studyType":24,"phases":305,"briefSummary":306,"conditions":307,"keywords":308,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":4},"100639059","phase-1-a-study-of-gsk4771261-in-healthy-participants-aged-25-to-55-years-of-age-inclusive-100639059","NCT07600450","A Study of GSK4771261 in Healthy Participants Aged 25 to 55 Years of Age Inclusive","A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Pharmacodynamics of GSK4771261 Administered as a Single Subcutaneous Dose to Healthy Participants of Chinese, Japanese and White\u002FEuropean Ancestry Aged 25 to 55 Years of Age Inclusive","Inclusion Criteria:\n\n* Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, and laboratory tests. A participant with a clinical abnormality or laboratory parameter(s) which is\u002Fare not specifically listed in the inclusion or exclusion criteria, outside the normal reference range for the population being studied may be included only if the Investigator, in their clinical judgement, believes and documents that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.\n* Body weight at least 50.0 kilograms (kg) for male participants or at least 45.0 kg for female participants at screening\n* Body Mass Index (BMI) within the range of 18.0 - 28.0 kilogram per square meters (kg\u002Fm\\^2) (inclusive) at screening\n* A female participant is eligible to participate if she is not pregnant or breastfeeding, and is a Participant of non-childbearing potential (PONCBP)\n* Capable of giving signed informed consent\n* Participants of Chinese ancestry or Japanese ancestry or White\u002FEuropean ancestry are eligible based on meeting all the following criteria:\n* Participants of Chinese ancestry: Born in mainland China, Hong Kong, or Taiwan; descendant of 4 ethnic Chinese grandparents and 2 ethnic Chinese parents; and have lived outside mainland China, Hong Kong, or Taiwan for less than 10 years at the time of screening\n* Participants of Japanese ancestry: born in Japan; descendant of 4 ethnic Japanese grandparents and 2 ethnic Japanese parents; and have lived outside Japan for less than 10 years at the time of screening\n* Participants of White\u002FEuropean ancestry: Self-identified as being of White\u002FEuropean ancestry (i.e., from the original peoples of Europe) irrespective of place of birth and current place of residence; and descendant of 4 grandparents and 2 parents of White\u002FEuropean ancestry (i.e., from the original peoples of Europe) irrespective of place of birth or current place of residence.\n\nExclusion Criteria:\n\n* History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention; or interfering with the interpretation of data\n* History of kidney disease or kidney abnormalities or Estimated glomerular filtration rate (eGFR) less than (\\\u003C) 90 millilitres per minute per 1.73 square meter (mL\u002Fmin\u002F1.73m\\^2) (based on the Chronic Kidney Disease Epidemiology Collaboration \\[CKD-EPI\\] 2021 eGFR equation) at screening and on Day -1\n* Significant allergies to humanized monoclonal antibodies\n* Clinically significant multiple or severe drug allergies, intolerance to topical corticosteroids, or severe post-treatment hypersensitivity reactions (including, but not limited to, erythema multiforme major, linear IgA dermatosis, toxic epidermal necrolysis, and exfoliative dermatitis)\n* Current or previous diagnosis of diabetes mellitus (type 1 or type 2)\n* Glycosylated hemoglobin (HbA1c) greater than or equal (\\>=)39 millimoles per mole (mmol\u002Fmol) at screening\n* Bone fracture within 6 months prior to screening, or presence of a known unresolved or incompletely resolved fracture\n* Have a history of malignant neoplasm (excepting definitively treated non-melanoma skin cancer or carcinoma in situ of the uterine cervix, which may be enrolled at any time) within the last 5 years\n* Current thyroid disease or history of thyroid disease\n* Presence of an incompletely healed wound at screening and\u002For planned surgical procedure that would occur during study\n* Intended use of over-the-counter or prescription medication, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study drug and for the duration of study participation (up to discharge on Day 8), unless, in the clinical judgement of the investigator, the medication will not interfere with the study procedures or compromise participant safety. Paracetamol (acetaminophen), at doses of \\\u003C= 4 grams per day (g\u002Fday) is permitted for use at any time during the study\n* Treatment with biologic agents (such as monoclonal antibodies including marketed drugs) or investigational drugs within 3 months or 5 half-lives (whichever is longer) prior to dosing\n* Donation or loss of more than 450 millilitres (mL) of blood within 60 days prior to study drug administration. Donation or loss of more than 1.5 Liters (L) of blood (for male participants)\u002Fmore than 1.0 L of blood (for female participants) in the 10 months prior to study drug administration in the current study\n* Current enrolment or past participation in an investigational clinical trial in which an investigational medicinal product was administered within the following time periods prior to the first dosing day of the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product, whichever is longer\n* Exposure to more than 4 investigational medicinal products within 12 months prior to dosing in current study\n* Positive preclinical study drug\u002Falcohol screen, including tetrahydrocannabinol\n* Evidence at screening of clinically significant hematological disorder (affecting hemoglobin, Red Blood Cells \\[RBC\\], White Blood Cells \\[WBC\\] or platelets) or abnormal blood clotting parameters\n* Prothrombin time (PT) or activated partial thromboplastin time (aPTT) \\>1.5\\*upper limit of normal (ULN) at screening\n* History or presence of excessive bleeding or coagulation disorders that in the opinion of the Investigator (in discussion with the GSK medical monitor as needed) poses a safety risk with regards to participation in the trial\n* Positive HIV antibody test\n* Presence of hepatitis B surface antigen (HBsAg) and\u002For hepatitis B core antibody (HBcAb) at screening or within 3 months prior to first dose of study intervention\n* Positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study intervention\n* Positive hepatitis C RNA test result at screening or within 3 months prior to first dose of study intervention\n* Regular use of any recreational drugs, including tetrahydrocannabinol\n* Participants who are unable to refrain use of combustible tobacco products, and non-combustible nicotine delivery systems, inclusive of cigarettes, cigars, pipes, and materials used to \"vape\" during study visits or overnight stays\n* Regular alcohol consumption within 6 months prior to the clinical study defined as: for sites in the Netherlands an average weekly intake of \\>21 units for males or for females. One unit of alcohol is equivalent to 10 g pure alcohol: a half-pint (approximately 250 mL) of beer (5 percent \\[%\\]), 1 glass (100 mL of wine \\[12%\\] or 1 measure (25 mL) of spirits \\[35%\\]\n* Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the investigator, in consultation with the medical monitor if required, contraindicates participation in the study\n* Use of any products intended to treat medical conditions that are not approved by the governing health authority in a given country or region (for example, herbal medicine, health supplements, traditional medicine, homeopathic remedies, etc.)\n* Sensitivity to heparin or a history of heparin-induced thrombocytopenia\n* Alanine transaminase (ALT) \\>1.5\\*(ULN at screening\n* Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)\n* Total bilirubin \\>1.5\\*ULN at screening; Participants with Gilbert's syndrome can be included with total bilirubin \\\u003C=3.0xULN as long as direct bilirubin is \\\u003C=1.0xULN\n* QTc \\>450 milliseconds (msec) or QTc \\>480 msec for participants with bundle branch block","25 Years","55 Years",{"count":138,"type":23},[166],"This is a first time in Asia (FTIA) study of GSK4771261 in healthy participants of Chinese, Japanese, and White\u002FEuropean ancestry. The study will test whether GSK4771261 is safe, well-tolerated, how it is processed in the body, and whether it triggers an immune response.",[32],[309,310,311,312,313,314,315,316],"GSK4771261","Healthy Volunteers","Pharmacokinetics","Pharmacodynamics","Immunogenicity","Chinese Ancestry","Japanese Ancestry","White\u002FEuropean Ancestry","2026-05-14",{"date":319,"type":45},"2026-05-20",{"date":321,"type":23},"2026-05-15",{"date":323,"type":23},"2026-09-22",{"name":325,"class":117},"GlaxoSmithKline",{"id":327,"slug":328,"hasResults":12,"nctId":329,"briefTitle":330,"officialTitle":331,"acronym":4,"eligibilityCriteria":332,"healthyVolunteers":12,"sex":18,"minAge":60,"maxAge":333,"enrollmentInfo":334,"targetDuration":4,"studyType":24,"phases":336,"briefSummary":337,"conditions":338,"keywords":341,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":348,"completionDateStruct":350,"leadSponsor":352,"locationsCount":92},"100637286","red-propolis-supplementation-as-a-strategy-in-chronic-kidney-disease-100637286","NCT07597005","Red Propolis Supplementation as a Strategy in Chronic Kidney Disease","Red Propolis as a Strategy to Modulate Inflammation and Oxidative Stress in Patients With Chronic Kidney Disease","Inclusion Criteria:\n\n* patients with CKD stages 3-5 under conservative management\n\nExclusion Criteria:\n\n* pregnant,\n* lactating,\n* smoker\n* patients using antibiotics and antioxidant supplements in the last three months\n* patients with autoimmune and infectious diseases,\n* patients with cancer, liver disease, and AIDS","65 Years",{"count":335,"type":23},40,[65],"The objective of this study is to evaluate the effects of red propolis on inflammation and oxidative stress in patients with chronic kidney disease on conservative management.",[32,339,169,340],"Oxidative Stress","Inflammation",[342,343,344,345],"oxidative stress","red propolis","inflammation","chronic kidney disease","2026-05-12",{"date":286,"type":45},{"date":349,"type":45},"2025-09-30",{"date":351,"type":23},"2027-08-31",{"name":353,"class":52},"Universidade Federal Fluminense",{"id":355,"slug":356,"hasResults":12,"nctId":357,"briefTitle":358,"officialTitle":359,"acronym":4,"eligibilityCriteria":360,"healthyVolunteers":12,"sex":18,"minAge":60,"maxAge":4,"enrollmentInfo":361,"targetDuration":4,"studyType":24,"phases":363,"briefSummary":364,"conditions":365,"keywords":370,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":373,"startDateStruct":374,"completionDateStruct":375,"leadSponsor":377,"locationsCount":92},"100626153","optimizing-referral-pathways-for-patients-with-hematuria-and-moderate-severe-proteinuria-100626153","NCT07431931","Optimizing Referral Pathways for Patients With Hematuria and Moderate-Severe Proteinuria","Optimizing Referral Pathways for Patients With Hematuria and Moderate-Severe Proteinuria - Phase 2: A Quality Improvement Project","Inclusion Criteria:\n\n* Adults aged ≥18 years\n* Patients receiving care from any Geisinger primary care provider (record of an encounter with a Geisinger PCP within the last 2 years from date of survey implementation)\n* Patients with high-risk glomerulonephritis features i.e. positive test results for hematuria (urine dipstick result with blood 1+ or greater) and proteinuria (2+ or 3+ protein on dipstick or ACR≥300 mg\u002Fg or PCR ≥500 mg\u002Fg) collected within 12 months of index date.\n\nExclusion Criteria:\n\n* Patients with a nephrologist appointment in the last 12 months before the index date\n* Patients with a prior appointment with a nephrologist within the last 2 years before the positive urinalysis test for hematuria (1+ or greater)\n* Patients with a history of glomerulonephritis and\u002For kidney failure (dialysis or eGFR \\\u003C 15 mL\u002Fmin\u002F1.73m2, or kidney transplantation) at any time during the baseline\n* Patients receiving palliative care at any time during the baseline",{"count":362,"type":23},1200,[65],"The purpose of the study is to evaluate prospectively the impact of an electronic health record (EHR) alert on primary care providers' (PCP) referral to Nephrology of Geisinger patients with high risk signs (blood and protein in the urine) of glomerulonephritis. This will help quantify the relative effectiveness of EHR alerts on PCPs' referral patterns.",[366,367,368,369,32],"Referral and Consultation","Glomerulonephritis","Hematuria","Proteinuria",[371],"Hematuria; Proteinuria; Albuminuria; Glomerulonephritis; Clinical Decision Support; EHR Alert; Referral; Nephrology","2026-05-07",{"date":346,"type":45},{"date":151,"type":23},{"date":376,"type":23},"2027-12",{"name":378,"class":52},"Geisinger Clinic",{"id":380,"slug":381,"hasResults":12,"nctId":382,"briefTitle":383,"officialTitle":384,"acronym":385,"eligibilityCriteria":386,"healthyVolunteers":252,"sex":18,"minAge":60,"maxAge":387,"enrollmentInfo":388,"targetDuration":228,"studyType":232,"phases":4,"briefSummary":390,"conditions":391,"keywords":397,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":409,"locationsCount":92},"100602857","direct-to-patient-minimal-risk-biospecimen-and-data-collection-research-100602857","NCT07128966","Direct to Patient Minimal Risk Biospecimen and Data Collection Research","Joined Bio - JB-MR-250225, Direct to Patient Minimal Risk Research","JBMR","Inclusion Criteria:\n\n* Male or female, that are adults \\[have reached the Age of Majority = aged 18 to 90 in most US states; aged 19-90 in Alabama or Nebraska; aged 21-90 in Mississippi or Puerto Rico\\].\n* Have reviewed and signed a consent or e-consent form for this study. If a person with diminished decision-making capacity, their Legally Authorized Representative has reviewed and signed the consent for on their behalf.\n* Be willing to comply with all study procedures and be available for the duration of the study.\n* Meets requirements of a current request for research participation (e.g. has previous diagnosis of a medical condition of interest or laboratory results within a specific range).\n* Pregnant women may be enrolled in this study in accordance with 45 CFR Part 46 Subpart B.\n\nExclusion Criteria:\n\n* Unable to meet the Inclusion Criteria listed above.\n* Prisoners or children\n* Unable to provide the requested biospecimen(s), data or feedback without placing the individual at risk.","90 Years",{"count":389,"type":23},100000,"This study aims to help researchers better understand health conditions and develop improved tests, treatments, and cures for diseases. Joined Bio collects health data, lifestyle information, biological samples, and feedback from participants and provides this to qualified research partners.",[392,393,394,32,395,396],"Healthy","Lupus","Celiac","Chronic","Dermatologic",[398,399,400,401],"biospecimen","rare disease","participant","registry","2026-05-04",{"date":404,"type":45},"2026-05-05",{"date":406,"type":45},"2025-04-01",{"date":408,"type":23},"2036-09-01",{"name":410,"class":117},"Joined Bio",{"id":412,"slug":413,"hasResults":12,"nctId":414,"briefTitle":415,"officialTitle":416,"acronym":417,"eligibilityCriteria":418,"healthyVolunteers":252,"sex":18,"minAge":60,"maxAge":4,"enrollmentInfo":419,"targetDuration":4,"studyType":232,"phases":4,"briefSummary":421,"conditions":422,"keywords":4,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":426,"lastUpdatePostDateStruct":427,"startDateStruct":429,"completionDateStruct":430,"leadSponsor":432,"locationsCount":92},"100609665","rutgers-university-study-of-the-genetics-of-kidney-disease-100609665","NCT07217535","Rutgers University Study of the Genetics of Kidney Disease","The Rutgers University Study of the Genetics of Kidney Disease","rugcc-kd","Inclusion Criteria:\n\n* age 18 years or older\n* currently living in the United States\n* able to understand and follow written instructions in English\n* have access to the internet and a computer, laptop, tablet or smart phone\n* willing to provide written informed consent for participation\n* willing to provide DNA via a saliva sample using a collection kit mailed to the study participant's home\n* willing to complete a survey with questions about health related to the study of kidney disease\n\nExclusion Criteria:\n\n* Not able to meet or fulfill any of the inclusion criter",{"count":420,"type":23},50000,"The goal of this observational study is to learn more about how genes impact the risk of kidney disease. Anyone 18 or older living in the US is eligible, and a diagnosis of kidney disease is NOT required. Study participation is online, and it takes about 20 minutes to complete health surveys and request a saliva collection kit sent through US mail. In return, study participants may opt to receive information about their genetic ancestry at no cost.",[32,170,68,423,424,425],"Kidney Diseases","Kidney Diseases, Chronic","Kidney Diseases,Cystic","2026-04-23",{"date":428,"type":45},"2026-04-24",{"date":426,"type":45},{"date":431,"type":23},"2028-10-31",{"name":433,"class":52},"Rutgers, The State University of New Jersey",{"id":435,"slug":436,"hasResults":12,"nctId":437,"briefTitle":438,"officialTitle":438,"acronym":439,"eligibilityCriteria":440,"healthyVolunteers":12,"sex":18,"minAge":60,"maxAge":441,"enrollmentInfo":442,"targetDuration":4,"studyType":232,"phases":4,"briefSummary":444,"conditions":445,"keywords":448,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":454,"lastUpdatePostDateStruct":455,"startDateStruct":457,"completionDateStruct":459,"leadSponsor":461,"locationsCount":92},"100634690","transgender-analysis-of-nephrological-studies-focused-on-renal-metrics-100634690","NCT07542964","Transgender Analysis of Nephrological Studies Focused on Renal Metrics","TRANSFORM","Inclusion Criteria:\n\n* Diagnosed with gender dysphoria according to DSM-V\n* Expected to start gender-affirming hormone treatment in the upcoming month\n\nExclusion Criteria:\n\n* Current or prior use of gender-affirming hormone therapy\n* Participation in other studies\n* Concomitant use of medication (specifically: antihypertensive agents, products, antidepressants, antipsychotic agents)\n* Known kidney disease (eGFR \\\u003C 60 ml\u002Fmin; UACR \\> 2.5 mg\u002Fmmol)\n* Diabetes mellitus\n* A history of cardiovascular disease (myocardial infarction; cardiac surgery or revascularization, unstable angina, heart failure, transient ischemic attack, cerebrovascular disease, or a previously undiagnosed arrhythmia)\n* Known iodine-related allergies\n* Metal in the body (such as pacemaker, ICD, neurostimulator, cochlear implant, or other metal)\n* Pregnancy\n* Claustrophobia","40 Years",{"count":443,"type":23},60,"This study investigates how sex hormones affect kidney function in people undergoing gender-affirming hormone therapy (GAHT). We know men have a faster progression of kidney disease. Earlier studies suggest that the female sex hormone estradiol may have a protective effect on kidney function while the male sex hormone testosterone may have the opposite effect. But the reasons why this happens remain unclear. By studying participants undergoing (GAHT) we gain insight into the mechanisms by which testosterone and estradiol influence the kidneys. People undergoing GAHT provide a unique chance to study how sex hormones interact with the kidneys. The results may help us to understand why men and women exhibit differences in kidney disease development. This study will include 30 men and 30 women, aged 18 to 40, who start GAHT. Participants will have three study visits, two of which will happen during their scheduled healthcare appointments. During the first visit, a screening will take place to check if patients can take part in the study. At study visits before and after one year of therapy, kidney function is measured, kidney MRI is performed, urine is collected and a small sample of fat tissue. Taking part in the study does not delay the start of GAHT.",[32,446,447],"Kidney Injury","Transgender Individuals",[449,450,451,452,453],"Transgender individuals","Kidney disease","Kidney injury","Gender affirming hormone treatment","Sex hormones","2026-04-17",{"date":456,"type":45},"2026-04-21",{"date":458,"type":23},"2026-09",{"date":460,"type":23},"2028-09",{"name":462,"class":52},"Amsterdam UMC, location VUmc",{"id":464,"slug":465,"hasResults":12,"nctId":466,"briefTitle":467,"officialTitle":468,"acronym":469,"eligibilityCriteria":470,"healthyVolunteers":12,"sex":18,"minAge":60,"maxAge":333,"enrollmentInfo":471,"targetDuration":4,"studyType":232,"phases":4,"briefSummary":473,"conditions":474,"keywords":480,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":492,"startDateStruct":494,"completionDateStruct":495,"leadSponsor":497,"locationsCount":92},"100630810","renal-and-hepatic-abnormal-doppler-patterns-in-trauma-100630810","NCT07492511","Renal and Hepatic Abnormal Doppler Patterns in Trauma","Renal and hEpatiC abnoRmal dopplEr pAtterns iN Trauma: a Multicentre Prospective Observational Study","RECREANT","Inclusion Criteria:\n\n* Age 18-65 years;\n* Admission within 24h from traumatic injury;\n* ISS \\>15\n\nExclusion Criteria:\n\n1. Age \\\u003C18 or \\>65;\n2. Known heart failure (NYHA ≥II);\n3. Chronic kidney disease (any stage) or chronic RRT;\n4. Chronic respiratory disease needing home O₂ or ventilation;\n5. Radiological evidence of vascular or parenchymal renal injury on trauma CT precluding reliable Doppler assessment",{"count":472,"type":23},350,"The goal of this observational study is to learn about renal and hepatic blood flow abnormalities detected by bedside ultrasound in adult patients admitted to the intensive care unit (ICU) following major trauma.\n\nThe main questions it aims to answer are:\n\n* How reliably can trained operators measure renal Doppler and venous congestion scores (RDRI and VExUS) across different hospitals?\n* How common are abnormal kidney and liver blood flow patterns in major trauma patients during the first 72 hours of ICU admission?\n* Are these abnormal patterns associated with acute kidney injury or the need for mechanical ventilation?\n\nParticipants admitted to ICUs or high-dependency units (HDUs) with major trauma (Injury Severity Score \\>15) will undergo non-invasive bedside ultrasound assessments at admission and at 24, 48, and 72 hours. No additional treatments or interventions will be given as part of this study. Kidney function will also be checked at 6 months after hospital discharge.",[475,476,32,477,478,479],"Trauma (Including Fractures)","Trauma Patients","Hypovolemia","Hypervolemia","Kidney Failure",[481,482,483,484,485,486,487,488,489,490],"VEXUS","trauma","kidney injury","kidney failure","Venous congestion","renal perfusion","Renal Doppler resistive index","major trauma","Hemodynamic phenotyping","ICU","2026-03-19",{"date":493,"type":45},"2026-03-25",{"date":87,"type":45},{"date":496,"type":23},"2030-06-30",{"name":498,"class":499},"Azienda Usl di Bologna","OTHER_GOV",{"id":501,"slug":502,"hasResults":12,"nctId":503,"briefTitle":504,"officialTitle":505,"acronym":506,"eligibilityCriteria":507,"healthyVolunteers":12,"sex":18,"minAge":508,"maxAge":4,"enrollmentInfo":509,"targetDuration":4,"studyType":232,"phases":4,"briefSummary":511,"conditions":512,"keywords":515,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":520,"lastUpdatePostDateStruct":521,"startDateStruct":523,"completionDateStruct":525,"leadSponsor":527,"locationsCount":529},"100597551","sensor-based-congestion-alert-for-events-in-peritoneal-dialysis-scale-pd-100597551","NCT07059962","Sensor-based Congestion ALert for Events in Peritoneal Dialysis (SCALE-PD)","Sensor-based Congestion Alert for Events in Peritoneal Dialysis (SCALE-PD)","SCALE-PD","Inclusion Criteria:\n\n1. Age 21 years or older\n2. Able to speak and read English, or able to speak and read Spanish and has a caregiver or family member who speaks English and can provide assistance\n3. Able to stand on two bare feet unassisted\n4. Receiving automated peritoneal dialysis for the treatment of ESKD\n5. Followed on the Vantive Sharesource Remote Patient Management Platform\n\nExclusion Criteria:\n\n1. Undergoing or plan to undergo hemodialysis in the next 12 months\n2. Have a life expectancy of less than 12 months\n3. Are pregnant or plan to become pregnant during the next 12 months\n4. Weigh greater than 375 lbs\n5. Planned kidney transplant within the next 12 months\n6. Have an implanted neurostimulator system","21 Years",{"count":510,"type":23},125,"To explore the use of the Bodyport Cardiac Scale in predicting worsening of events due to fluid overload in patients with kidney disease on peritoneal dialysis.",[32,513,514],"Peritoneal Dialysis (PD)","End Stage Kidney Disease (ESRD)",[516,517,518,519],"kidney disease","peritoneal dialysis","fluid overload","heart failure","2026-03-17",{"date":522,"type":45},"2026-03-18",{"date":524,"type":45},"2025-09-09",{"date":526,"type":23},"2026-06",{"name":528,"class":117},"Bodyport Inc.",4,{"id":531,"slug":532,"hasResults":12,"nctId":533,"briefTitle":534,"officialTitle":535,"acronym":536,"eligibilityCriteria":537,"healthyVolunteers":12,"sex":18,"minAge":60,"maxAge":538,"enrollmentInfo":539,"targetDuration":4,"studyType":24,"phases":541,"briefSummary":542,"conditions":543,"keywords":545,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":547,"lastUpdatePostDateStruct":548,"startDateStruct":550,"completionDateStruct":551,"leadSponsor":552,"locationsCount":554},"100630238","digital-support-for-reducing-salt-intake-among-patients-with-diabetic-kidney-disease-protocol-for-a-controlled-clinical-trial-100630238","NCT07485075","Digital Support for Reducing Salt Intake Among Patients With Diabetic Kidney Disease: Protocol for a Controlled Clinical Trial","SBI 2024-2026 STENO FOOD CONCEPT","StenoFOODApp","Inclusion Criteria:\n\n* Type 2 diabetes (ICD-10 DE11.x)\n* Age 18-74 years\n* BMI \\\u003C 35 kg\u002Fm²\n* eGFR 30-59 ml\u002Fmin and UACR \\> 30 mg\u002Fg\n* Stable medication for ≥3 months\n* Ability to read and understand Danish\n\nExclusion Criteria:\n\n* Type 1 diabetes or other diabetes types\n* Current vegan diet\n* Active cancer\n* Short bowel syndrome or celiac disease\n* Use of sodium chloride tablets\n* No access to digital platform (intervention group only)","74 Years",{"count":540,"type":23},104,[65],"This study evaluates whether a digital patient education program can improve adherence to KDIGO 2022 dietary recommendations (low sodium and optimal protein intake) among patients with type 2 diabetes and chronic kidney disease (eGFR 30-59 ml\u002Fmin).",[544,32],"Diabetes Type 2",[546],"Type 2 Diabetes, Chronic Kidney Disease, Digital Health, Dietary Intervention, KDIGO Guidelines","2026-03-16",{"date":549,"type":45},"2026-03-20",{"date":549,"type":23},{"date":292,"type":23},{"name":553,"class":52},"Steno Diabetes Center Copenhagen",2,{"id":556,"slug":557,"hasResults":12,"nctId":558,"briefTitle":559,"officialTitle":560,"acronym":4,"eligibilityCriteria":561,"healthyVolunteers":252,"sex":18,"minAge":60,"maxAge":562,"enrollmentInfo":563,"targetDuration":4,"studyType":24,"phases":565,"briefSummary":566,"conditions":567,"keywords":4,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":573,"lastUpdatePostDateStruct":574,"startDateStruct":576,"completionDateStruct":578,"leadSponsor":580,"locationsCount":554},"100625726","phase-1-a-study-of-eloralintide-ly3841136-in-participants-with-renal-impairment-and-in-participants-with-normal-renal-function-100625726","NCT07426380","A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function","A Phase 1, Multicenter, Parallel-Design, Single Dose, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Eloralintide in Participants With Severe Renal Impairment and End Stage Renal Disease (ESRD) Compared With Participants With Normal Renal Function","Inclusion Criteria:\n\n* Have a body weight of 55 kilograms (kg) or more and a body mass index (BMI) within the range of 19.0 to 40.0 kilograms per square meter (kg\u002Fm²), inclusive\n* Have no significant history of spontaneous or ethanol-induced hypoglycemia\n\nAdditional Inclusion Criteria for Group 1\n\n* Are healthy as determined by medical history, physical examination, and other screening procedures, with normal renal function, assessed by estimated glomerular filtration rate (eGFR) of at least 90 milliliters per minute (mL\u002Fmin)\n* Have glycated hemoglobin (HbA1c) less than or equal to 6.5% at screening\n\nAdditional Inclusion Criteria for Groups 2 and 3\n\n* Have stable severe renal impairment, assessed by eGFR less than 30 mL\u002Fmin at screening or with end-stage renal disease (ESRD) who have been on a stable hemodialysis (HD) schedule for at least 3 months prior to planned dosing\n* Have acceptable blood pressure and pulse rate\n* If participants have Type 2 Diabetes Mellitus (T2DM), they must have a HbA1c equal to or less than 10.0% at screening\n\nExclusion Criteria:\n\n* Have a history of chronic liver disease, acute or chronic hepatitis, including a history of autoimmune hepatitis, any evidence for hepatic impairments\n* Have a current, functioning organ transplant. Nonfunctional renal allografts may be considered\n* Have significant history or current cardiovascular, respiratory, hepatic, renal, gastrointestinal (GI), endocrine, hematological, dermatological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the investigational product; or interfering with the interpretation of data\n\nGroups 2 and 3\n\n* Are receiving continuous HD or peritoneal dialysis.\n* Have used any drug indicated for medical care of the participant's renal impairment, which is not established in dose and administered for at least 7 days before eloralintide administration","85 Years",{"count":564,"type":23},28,[166],"The purpose of the study is to assess the amount of Eloralintide (LY3841136) that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment and to healthy participants. The study drug will be administered subcutaneously (SC) (under the skin).\n\nFor each participant, the study will last about 14 weeks, excluding screening.",[32,568,569,570,571,572],"Renal Insufficiency Chronic","Kidney Failure, Chronic","Renal Impairment","Renal Insufficiency","End Stage Kidney Disease","2026-03-12",{"date":575,"type":45},"2026-03-13",{"date":577,"type":45},"2026-02-24",{"date":579,"type":23},"2026-10",{"name":581,"class":117},"Eli Lilly and Company",{"id":583,"slug":584,"hasResults":12,"nctId":585,"briefTitle":586,"officialTitle":587,"acronym":588,"eligibilityCriteria":589,"healthyVolunteers":12,"sex":18,"minAge":590,"maxAge":4,"enrollmentInfo":591,"targetDuration":4,"studyType":24,"phases":593,"briefSummary":594,"conditions":595,"keywords":600,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":607,"lastUpdatePostDateStruct":608,"startDateStruct":610,"completionDateStruct":612,"leadSponsor":614,"locationsCount":4},"100625231","older-kidney-patient-optimisation-pretransplant-100625231","NCT07419945","Older Kidney Patient Optimisation Pretransplant","Optimising Access to and Outcomes From Transplantation in Older Potential Kidney Transplant Recipients: Pilot Feasibility Study on Kidney Transplant-specific Comprehensive Geriatric Assessment (KT-CGA)","OK-POP","Inclusion Criteria:\n\n* Adults aged 60 years or older\n* Attending Guy's and St Thomas' (GSTT) Nephrology services\n* Diagnosed with Chronic Kidney Disease (CKD) Stage 5\n\nEither:\n\n* Pre-dialysis, or\n* Receiving dialysis (in-centre haemodialysis, peritoneal dialysis, or home haemodialysis)\n* Referred to the kidney transplant surgical clinic for assessment of suitability for kidney transplantation (pre-transplant evaluation)\n\nExclusion Criteria:\n\n* Adults aged under 60 years\n* Patients currently attending the Nephrology Supportive Care service at GSTT","60 Years",{"count":592,"type":23},50,[65],"The goal of this clinical trial is to learn if a kidney transplant-specific comprehensive geriatric assessment (KT-CGA) can improve the way older adults are assessed for kidney transplantation. The main questions it aims to answer are:\n\nIs it feasible and acceptable to deliver a KT-CGA alongside routine transplant assessment in older adults with advanced kidney disease?\n\nWhat is the effect of KT-CGA on decision-making about transplant listing and on patient-reported outcomes such as quality of life and frailty?\n\nResearchers will compare participants who receive the KT-CGA plus usual care to those who receive usual care alone.\n\nParticipants will:\n\nContinue with their usual transplant assessment process\n\nIf randomised to the intervention group, also complete the KT-CGA (a structured set of questionnaires, short memory and function tests, and discussions about wellbeing and support needs, taking about 45-60 minutes)",[32,479,596,597,598,514,69,599],"Frailty","Cognitive Impairment","Multimorbidity","Health Inequity",[601,602,603,604,605,606],"kidney transplant","frailty","multimorbidity","cognitive impairment","end stage kidney disease","health inequality","2026-02-12",{"date":609,"type":45},"2026-02-19",{"date":611,"type":23},"2026-02-02",{"date":613,"type":23},"2028-02-02",{"name":615,"class":52},"Guy's and St Thomas' NHS Foundation Trust",{"id":617,"slug":618,"hasResults":12,"nctId":619,"briefTitle":620,"officialTitle":621,"acronym":622,"eligibilityCriteria":623,"healthyVolunteers":12,"sex":18,"minAge":60,"maxAge":4,"enrollmentInfo":624,"targetDuration":4,"studyType":24,"phases":626,"briefSummary":627,"conditions":628,"keywords":4,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":631,"lastUpdatePostDateStruct":632,"startDateStruct":633,"completionDateStruct":635,"leadSponsor":637,"locationsCount":268},"100623979","cardiovascular-kidney-and-metabolic-health-assessment-and-patient-empowerment-100623979","NCT07403669","Cardiovascular Kidney and Metabolic Health Assessment and Patient Empowerment","Cardiovascular Kidney and Metaboolic (CKM) Health Assessment and Patient Empowerment in chROnic Disease Using a Health Coach INtervention ModEl: A Randomized Clinical Trial","CHAPERONE-CKM","Inclusion Criteria:\n\n* Men and women over 18 years of age are included\n* Eligible subjects must have one of the risk factor\u002F disease component of CKM:\n* Diabetes with A1C of 7.5 or higher;\n* or Heart disease with stent placement;\n* or Coronary Artery Bypass Graft (CABG) in the last 12 months;\n* or Chronic Kidney Disease (CKD) stage 2- 4\n* and, in those with Heart failure, a recent hospitalization within one week of enrollment is required\n\nExclusion Criteria:\n\n* Those subjects who are not willing to sign an informed consent",{"count":625,"type":23},300,[65],"The primary objective of CHAPERONE solution is to evaluate the efficacy of engaging, assessing, and enabling long term treatment strategy with Health Artificial Intelligence (AI) Chatbot, Copilot, Large Language Model (LLM) and vital sign monitoring device in reducing CKM disease burden using an algorithm obtained from biomarkers and diagnostics utilizing remote sensor driven technology tools, care coordination and patient empowerment.",[629,281,630,32],"Acute MI","Diabetes Mellitus","2026-02-10",{"date":607,"type":45},{"date":634,"type":45},"2025-10-22",{"date":636,"type":23},"2027-04-22",{"name":638,"class":117},"Aventyn, Inc.",{"id":640,"slug":641,"hasResults":12,"nctId":642,"briefTitle":643,"officialTitle":644,"acronym":645,"eligibilityCriteria":646,"healthyVolunteers":12,"sex":18,"minAge":647,"maxAge":4,"enrollmentInfo":648,"targetDuration":4,"studyType":232,"phases":4,"briefSummary":650,"conditions":651,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":659,"lastUpdatePostDateStruct":660,"startDateStruct":662,"completionDateStruct":664,"leadSponsor":666,"locationsCount":4},"100622045","cobas-lumira-collection-of-venous-and-capillary-blood-samples-for-the-research-optimization-and-calibration-of-new-diagnostic-devices-100622045","NCT07378514","Cobas® Lumira Collection of Venous and Capillary Blood Samples for the Research, Optimization and Calibration of New Diagnostic Devices","Cobas® Lumira Collection of Venous and Capillary Blood Samples for the Research, Optimization and Calibration of New Diagnostic Devices (EVOLVE)","EVOLVE","Inclusion Criteria:\n\n1. Willing and able to provide written informed consent.\n2. Willing to comply with study procedures.\n3. The participant must present as one of the following cohorts (primary presenting condition):\n\n   * Cohort A - Embolism Cohort (participants presenting with symptoms indicative of thromboembolic events)\n   * Cohort B - Infection or Inflammation Cohort (participants presenting with symptoms indicative of infection or inflammatory disorders)\n   * Cohort C - Cardiovascular Cohort (participants presenting with symptoms indicative of heart failure or acute coronary syndrome)\n   * Cohort D - Renal Cohort (participants presenting with symptoms indicative of renal disorders)\n   * Cohort E - Oral Anticoagulation Cohort (participants with ongoing vitamin K antagonist therapy for at least four weeks)\n   * Cohort F - Diabetes Cohort (participants with suspected pre-Diabetes or diagnosed with Diabetes Mellitus Type 1 or Type 2)\n   * Cohort G - Lipid Cohort (participants presenting with symptoms indicative for Hypercholesterolemia )\n   * Cohort H - Liver Cohort (participants with symptoms indicative of hepatic disorders).\n\nInclusion Criteria for Cohorts A, B, C, D, E, G, and H:\n\n1\\. Participants ≥ 18 years of age\n\nInclusion Criteria for Cohort F (Diabetes Cohort):\n\n1\\. Participants ≥ 16 years old\n\nExclusion Criteria:\n\n1. Subjects deemed inappropriate for the study by the Principal Investigator.\n2. Participants who have previously been enrolled in the EVOLVE study in the past 60 days.\n\nExclusion Criteria for Cohort E (Oral Anticoagulation Cohort):\n\n1. Subjects who are currently taking non-vitamin K antagonist oral anticoagulants (NOACs) including but not limited to apixaban, dabigatran etexilate, edoxaban and rivaroxaban.\n2. Subjects who have anti-phospholipid antibody syndrome (APS)\n3. The participant is currently receiving or has received within the past thirty (30) days of the study visit an experimental biologic, experimental drug, or experimental device including either treatment or therapy.","16 Years",{"count":649,"type":23},30000,"This study is a blood sample collection study, collecting venous and capillary blood samples from adult patients in the UK, with a range of health conditions. The purpose of this study is to collect blood samples to help develop, improve, and fine-tune new and existing diagnostic tests for the cobas® lumira instrument. This instrument is a diagnostic medical device with single-use test strips, that allows diagnostic testing right at the patient's side. The aim is to improve doctors' ability to monitor health conditions more quickly and easily.\n\nApproximately 30,000 patients are expected to participate in this study, across multiple UK sites.",[652,653,654,32,655,656,657,658],"Blood Clots","Infection and Inflammatory Reaction","Heart Disease","Vitamin K Antagonist","Diabetes","High Cholesterol","Liver Disease","2026-01-22",{"date":661,"type":45},"2026-01-30",{"date":663,"type":23},"2026-04",{"date":665,"type":23},"2031-07",{"name":667,"class":117},"LumiraDx UK Limited",{"id":669,"slug":670,"hasResults":12,"nctId":671,"briefTitle":672,"officialTitle":673,"acronym":4,"eligibilityCriteria":674,"healthyVolunteers":12,"sex":18,"minAge":60,"maxAge":4,"enrollmentInfo":675,"targetDuration":4,"studyType":24,"phases":677,"briefSummary":679,"conditions":680,"keywords":683,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":691,"lastUpdatePostDateStruct":692,"startDateStruct":693,"completionDateStruct":695,"leadSponsor":697,"locationsCount":700},"100564123","phase-4-randomized-trial-of-sglt2i-in-heart-transplant-recipients-100564123","NCT06625073","Randomized Trial of SGLT2i in Heart Transplant Recipients","Randomized Trial of Sodium-glucose Cotransporter 2 Inhibition in Heart Transplant Recipients","Inclusion Criteria:\n\n1. Age 18 years or older\n2. Heart transplant recipient, 3 months after transplant\n\nExclusion Criteria:\n\n1. eGFR \\\u003C20 mL\u002Fmin\u002F1.73m2\n2. Type 1 diabetes mellitus\n3. HbA1C \\>10%\n4. Baseline UACR \\\u003C30 mg\u002Fg in patients without T2D\n5. Known allergy or intolerance to SGLT2i\n6. Active uncontrolled infection\n7. Multiorgan transplant\n8. SGLT2i treatment in the last 30 days\n9. Pregnancy, breast-feeding or woman of child-bearing age not on birth control",{"count":676,"type":23},200,[678],"PHASE4","Heart transplant (HTx) is an established therapy for advanced heart disease that restores quality of life and improves survival. However, due to preexisting comorbidities combined with the immunosuppressive therapies required after transplantation, HTx recipients remain at high risk for kidney, cardiovascular (CV), and metabolic disease. Large randomized clinical trials have recently shown that sodium-glucose cotransporter 2 inhibitors (SGLT2i) have potent kidney protective and CV benefits in many populations of patients with chronic kidney disease (CKD), CV disease and\u002For diabetes. SGLT2i have not been studied prospectively in HTx recipients, which represents a barrier to their use in this population.\n\nIn this multicenter randomized controlled trial in Veterans with HTx, investigators will evaluate the potential benefits of empagliflozin on kidney function, cardiometabolic risk, erythropoiesis, and functional status. A total of 200 Veterans will be randomly assigned to receive either empagliflozin 10 mg daily or a matching placebo for 12 months.",[681,682,32],"Heart Transplant","Cardiovascular Disease",[681,684,685,686,687,688,689,690],"Empagliflozin","Safety and Tolerability","Kidney Outcomes","Cardiometabolic Outcomes","Erythropoiesis","Functional Status","Quality of Life","2026-01-21",{"date":659,"type":45},{"date":694,"type":45},"2026-01-20",{"date":696,"type":23},"2030-02-28",{"name":698,"class":699},"VA Office of Research and Development","FED",6,{"id":702,"slug":703,"hasResults":12,"nctId":704,"briefTitle":705,"officialTitle":705,"acronym":4,"eligibilityCriteria":706,"healthyVolunteers":12,"sex":707,"minAge":19,"maxAge":20,"enrollmentInfo":708,"targetDuration":4,"studyType":24,"phases":710,"briefSummary":711,"conditions":712,"keywords":718,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":721,"lastUpdatePostDateStruct":722,"startDateStruct":724,"completionDateStruct":726,"leadSponsor":728,"locationsCount":92},"100590349","inspire-her-inspiring-the-heart-and-emotions-for-radical-health-100590349","NCT06966258","Inspire HER: Inspiring the Heart and Emotions for Radical Health","Inclusion Criteria:\n\n* Black women (self-report)\n* Adult ages 30-79 years\n* Stage 2 or greater Cardiovascular-Kidney-Metabolic Syndrome\n* English speaking\n* Lives in Metropolitan Birmingham, AL area.\n\nExclusion Criteria:\n\n\\- Healthcare provider-imposed physical activity limitations.","FEMALE",{"count":709,"type":23},90,[65],"Poor heart health puts Black women at risk for a shorter life with more illness than people of any other non-indigenous racial group. We will refine and conduct a randomized, wait-list controlled trial of Inspire HER (a heart health lifestyle intervention for Black women that provides health education, physical activity, and social resources). We will also compare Inspire HER and Black Impact (a heart health intervention for Black men) data to study how women and men respond differently to stress. This trial aligns with American Heart Association's pledge to address heart health equity through new interventions that consider the person and the circumstances with which they live.",[713,714,715,656,716,32,33,717],"Cardiovascular-kidney-metabolic Syndrome","Cardiovascular Diseases","Hypertension","Hyperlipidemia","Smoking",[719,720],"Cardiovascular Risk","Lifestyle intervention","2025-12-19",{"date":723,"type":45},"2025-12-29",{"date":725,"type":45},"2025-11-15",{"date":727,"type":23},"2029-03-31",{"name":729,"class":52},"University of Alabama at Birmingham"]